Botulinum Toxin Nerve-Zone Targeting for Post-Traumatic Headache

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current FDA-approved methods for treating migraines using Botulinum toxin suffer from sporadic treatment coverage, limited nerve targeting, and unwanted side effects due to low dosing and intramuscular administration, which do not effectively address the broader nerve networks responsible for migraine symptoms.

Innovation Solution

Administer higher doses and larger volumes of Botulinum toxin extramuscularly to specific nerve cluster zones and exit points in the head and neck, avoiding muscle tissue to ensure uniform coverage of sensory nerves and reduce side effects.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If intramuscular administration of Botulinum toxin is used for migraine treatment, then the toxin can be delivered to muscle tissue, but this causes unwanted side effects including muscle paralysis and does not effectively target sensory nerves

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidmuscle paralysis side effects

Core Design Contradiction:

ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent inverts the traditional intramuscular administration approach by using extramuscular administration. Instead of injecting Botulinum toxin into muscle tissue, the invention delivers the toxin extramuscularly to sensory nerves in the head and neck region, thereby avoiding muscle paralysis side effects while maintaining treatment effectiveness for migraine prevention

Inventive Principle:

Principle #13The other way round (Inversion)

Solution Approach 2:

The patent uses extramuscular administration as an intermediary method between the Botulinum toxin and the target sensory nerves. This intermediate approach allows the toxin to reach the nerves without passing through muscle tissue, thus avoiding the harmful muscle paralysis effect while still achieving the desired nerve targeting for migraine treatment

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-generated harmful factors

If low dosing of Botulinum toxin is used, then side effects are reduced, but treatment coverage becomes sporadic and nerve targeting is limited

Engineering Contradiction:

Improveside effectsVSAvoidtreatment coverage

Core Design Contradiction:

Object-generated harmful factorsVSReliability

Solution Approach 1:

The patent changes the administration parameters from intramuscular to extramuscular route, and adjusts the dosing strategy to provide higher total doses distributed across multiple extramuscular injection sites. This parameter change allows adequate nerve coverage while managing side effects through targeted delivery rather than relying on low dosing alone

Inventive Principle:

Principle #35Parameter changes

3Ease of manufacture

If traditional migraine treatment methods are used, then standard care is provided, but they do not effectively address the broader nerve networks responsible for migraine symptoms

Engineering Contradiction:

Improvestandard of careVSAvoidsymptom reduction

Core Design Contradiction:

Ease of manufactureVSReliability

Solution Approach 1:

The patent segments the treatment approach by identifying and targeting specific nerve cluster zones in the head and neck region where sensory nerves are located. Instead of using a one-size-fits-all standard treatment, the invention divides the treatment area into specific zones (frontal, temporal, parietal, occipital) with corresponding nerve clusters, allowing targeted Botulinum toxin delivery to the specific nerve networks responsible for migraine symptoms

Inventive Principle:

Principle #1Segmentation

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

This approach provides more effective treatment of migraines by saturating the nerve networks associated with migraine symptoms while minimizing muscle paralysis, leading to improved symptom reduction and prevention.

Implementation Method 1

The present specification discloses methods and uses for treating a migraine disorder using a Botulinum toxin

Methodology Applied

Scientific EffectBotulinum toxin mechanism:

Data Source

PatentUS12533400B2Zonal and targeted methods and uses for treating a chronic post-traumatic headache associated with a post-traumatic stress disorder

Publication Date: 2026.01.27 MIOTOX LLC

AI summary

The present specification discloses methods for treating a PTSD. The methods comprise extramuscularly administering a Botulinum toxin to an individual in one or more areas of a fronto-fascial layer located in a frontal head region, one or more areas of a temporoparietal-fascial layer located in a temporal head region, and one or more areas of an occipito-fascial layer located in an occipital head region. The methods further comprise extramuscularly administering a Botulinum toxin to one or more nerve exit points and/or one or more subcutaneous locations in the head and neck and/or one or more sites of an epicranial aponeurosis. The methods further comprise intramuscularly administering a Botulinum toxin to one or more locations within the left and right Splenius Capitis muscle, the left and right Masseter muscles, the left and right Trapezius muscles, or any combination thereof.